137 related articles for article (PubMed ID: 8868112)
1. Synthesis and biological evaluation of proline derivatives as potential angiotensin converting enzyme inhibitor.
Giugliano G; Grieco P; Ialenti A; Mottola M; Perissutti E; Santagada V
Boll Soc Ital Biol Sper; 1996; 72(1-2):29-36. PubMed ID: 8868112
[TBL] [Abstract][Full Text] [Related]
2. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of 2-substituted-N-carboxymethyl-1,5-benzothiazepin-4-ones and -1,4-benzothiazin-3-ones and their evaluation as angiotensin converting enzyme inhibitors.
Trapani G; Latrofa A; Franco M; Liso G
Farmaco; 1995 Feb; 50(2):107-12. PubMed ID: 7766274
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship study between Ornithyl-Proline and Lysyl-Proline based tripeptidomimics as angiotensin-converting enzyme inhibitors.
Pavar MC; Hanif K; Azam A; Lata S; Qadar Pasha MA; Pasha S
Bioorg Med Chem Lett; 2006 Apr; 16(8):2117-21. PubMed ID: 16464585
[TBL] [Abstract][Full Text] [Related]
5. Novel ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular modelling.
Redelinghuys P; Nchinda AT; Chibale K; Sturrock ED
Biol Chem; 2006 Apr; 387(4):461-6. PubMed ID: 16606345
[TBL] [Abstract][Full Text] [Related]
6. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.
Georgiadis D; Cuniasse P; Cotton J; Yiotakis A; Dive V
Biochemistry; 2004 Jun; 43(25):8048-54. PubMed ID: 15209500
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of angiotensin converting enzyme by L-alanyl-4 or 5-substituted-L-prolines and their N alpha-phosphoryl-derivatives.
Alexandrou EN; Liakopoulou-Kyriakides M
Biochem Int; 1990; 21(2):271-8. PubMed ID: 2403366
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and enzyme inhibitory activities of new trifluoromethyl-containing inhibitors for angiotensin converting enzyme.
Ojima I; Jameison FA; Pete B; Radunz H; Schittenhelm C; Lindner HJ; Emith AE
Drug Des Discov; 1994 Feb; 11(2):91-113. PubMed ID: 8075303
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors.
Nchinda AT; Chibale K; Redelinghuys P; Sturrock ED
Bioorg Med Chem Lett; 2006 Sep; 16(17):4612-5. PubMed ID: 16784850
[TBL] [Abstract][Full Text] [Related]
10. The synthesis and angiotensin converting enzyme (ACE) inhibitory activity of chalcones and their pyrazole derivatives.
Bonesi M; Loizzo MR; Statti GA; Michel S; Tillequin F; Menichini F
Bioorg Med Chem Lett; 2010 Mar; 20(6):1990-3. PubMed ID: 20167484
[TBL] [Abstract][Full Text] [Related]
11. ACE inhibitors hypothesis generation for selective design, synthesis and biological evaluation of 3-mercapto-2-methyl-propanoyl-pyrrolidine-3-imine derivatives as antihypertensive agents.
Ismail MA; Nabil Aboul-Enein M; Abouzid KA; Abou El Ella DA; Ismail NS
Bioorg Med Chem; 2009 May; 17(10):3739-46. PubMed ID: 19403313
[TBL] [Abstract][Full Text] [Related]
12. Structure-function studies of BPP-BrachyNH
Arcanjo DDR; Vasconcelos AG; Nascimento LA; Mafud AC; Plácido A; Alves MMM; Delerue-Matos C; Bemquerer MP; Vale N; Gomes P; Oliveira EB; Lima FCA; Mascarenhas YP; Carvalho FAA; Simonsen U; Ramos RM; Leite JRSA
Eur J Med Chem; 2017 Oct; 139():401-411. PubMed ID: 28810191
[TBL] [Abstract][Full Text] [Related]
13. Probing the importance of spacial and conformational domains in captopril analogs for angiotensin converting enzyme activity.
Hanessian S; Reinhold U; Saulnier M; Claridge S
Bioorg Med Chem Lett; 1998 Aug; 8(16):2123-8. PubMed ID: 9873498
[TBL] [Abstract][Full Text] [Related]
14. Procyanidin structure defines the extent and specificity of angiotensin I converting enzyme inhibition.
Ottaviani JI; Actis-Goretta L; Villordo JJ; Fraga CG
Biochimie; 2006; 88(3-4):359-65. PubMed ID: 16330143
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological activity of angiotensin converting enzyme inhibitors: N-(mercaptoacyl)-4-substituted-(S)-prolines.
Smith EM; Swiss GF; Neustadt BR; Gold EH; Sommer JA; Brown AD; Chiu PJ; Moran R; Sybertz EJ; Baum T
J Med Chem; 1988 Apr; 31(4):875-85. PubMed ID: 2832605
[TBL] [Abstract][Full Text] [Related]
16. Relationship between metabolism and pharmacologic activity of SQ 27,786, an angiotensin converting enzyme inhibitor with potent diuretic activity.
Everett DW; Singhvi SM; DeForrest JM; Morrison RA; Weinstein SH; Migdalof BH
Drug Des Deliv; 1987 Sep; 2(1):23-34. PubMed ID: 3509342
[TBL] [Abstract][Full Text] [Related]
17. Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2.
Mores A; Matziari M; Beau F; Cuniasse P; Yiotakis A; Dive V
J Med Chem; 2008 Apr; 51(7):2216-26. PubMed ID: 18324760
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of novel 2-butyl-4-chloro-1-methylimidazole embedded chalcones and pyrazoles as angiotensin converting enzyme (ACE) inhibitors.
Kantevari S; Addla D; Bagul PK; Sridhar B; Banerjee SK
Bioorg Med Chem; 2011 Aug; 19(16):4772-81. PubMed ID: 21782455
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin converting enzyme inhibitors as antihypertensive agents: 1-[(2-mercaptocycloalkyl)carbonyl]-L-prolines.
Ciabatti R; Padova G; Bellasio E; Tarzia G; Depaoli A; Battaglia F; Cellentani M; Barone D; Baldoli E
J Med Chem; 1986 Mar; 29(3):411-7. PubMed ID: 3005576
[TBL] [Abstract][Full Text] [Related]
20. Modification of the furanacryloyl-L-phenylalanylglycylglycine assay for determination of angiotensin-I-converting enzyme inhibitory activity.
Murray BA; Walsh DJ; FitzGerald RJ
J Biochem Biophys Methods; 2004 May; 59(2):127-37. PubMed ID: 15163524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
